Helpline 07939 046 030

A man on a mission: Onno Faber and his NF2 journey

14 October 2021

Onno Faber at a meeting to organize his hackathon. Photo courtesy of Onno Faber

This article features a series of five articles written by Grace Rubenstein and has been reversioned with permissions from NEO.LIFE 

Photo credits as listed

Find out more about onnofaber.com

Onno Faber was 33 and living in Berlin, launching a photo-sharing smartphone app, when he awoke one morning to a terrible sound in his left ear. Every noise around him, even a toilet flush, sounded like breaking glass. A series of medical tests produced no answers, until the day Onno walked into the doctor’s office and saw a bright circle, a tumor, in the image of his brain on the computer screen. And Onno thought, “F**k!”

Onno had Neurofibromatosis Type 2, or NF2, a rare disorder in which tumors grow in the nerve cells that enable hearing, balance, and movement. Doctors did not expect Onno’s case to kill him, but in time Onno would almost surely lose his hearing and perhaps his eyesight and mobility as well.

In the three years since that shock, Onno has transformed his initial grief into determination to do things in a groundbreaking way  -  by confronting biological fate with technological invention. His genre-bending quest brings cutting-edge gene sequencing together with artificial intelligence and the collaborative spirit of Silicon Valley to solve a medical puzzle. And though the gene mutation that causes NF2, which is sometimes hereditary, struck Onno at random, it turns out that he is just the right person, in just the right place, with just the right friends to do this.

Carry on reading Part One:

Onno Faber addresses the hackathon. Photo courtesty of Onno Faber

On a Friday summer evening in San Francisco, 150 smart young people flooded one floor of a South-of-Market office building and filled the space with their excited voices. Onno Faber, a Dutch tech entrepreneur with tousled blond hair, flitted among them, leaning in close with his right ear to hear each person above the hubbub. He was the reason they all had come.

“I don’t know anybody,” Onno said of the guests, who had traveled from universities and pharmaceutical companies across the country. Then he laughed and added: “But they will know me.”

The crowd had come to spend the weekend crunching the data of Onno’s DNA. They’d be searching for genetic clues in hopes of curing his Neurofibromatosis Type 2, or NF2  -  a rare disorder that had already stolen the hearing in his left ear and caused the tumors now growing slowly in his right hearing nerve and spine. Eventually they could wipe out the rest of his hearing, his sight, and his ability to walk.

Read Part Two:

Onno in San Francisco. Photo courtesy of Damien Maloney, NEO.LIFE

In a top-floor bedroom on the north side of Chicago, Alexandra White sat at a steel-and-glass desk in a sparkly red kitchenette chair and wrangled one iridescent disc after another into the CD drive on her laptop. She uploaded thousands of images from her brother’s medical records, along with nearly 150 pages that she had scanned. Fiery and determined, Alex pulled from a massive cup of coffee as she plowed through the task.

At the same time, she appeared on a computer screen in a cave-like meeting room in San Francisco, where a sunny-tempered tech entrepreneur named Onno Faber watched her every step with rapt attention. They went on this way on a video conference for hours, Alex uploading files and commenting on glitches in the process, Onno furiously typing lines of code.

This test run of Onno’s new software was a pivotal moment in his quest to transform the treatment of rare diseases like the ones he and Alex’s brother have. Onno is on a mission to combine the promise of genetics with newfound computational power to ignite research on neglected illnesses. And this session with Alex would help launch his next stage.

Continue reading Part Three:

Onno at a singing lesson in San Francisco. Photo courtesy of Winnie Wintermeyer, NEO.LIFE

Onno Faber, a 36-year-old tech entrepreneur, stands straight up in the center of a modest living room, his shoeless feet planted in the gray striped rug. He looks trustingly at the music teacher who faces him, flashing her his frequent, accepting smile. Then he takes a breath, lifts his clear tenor voice, and sings.

Tomorrow, Onno will be video conferencing with parents of children who have rare diseases, to pitch them on his new tech platform to propel unconventional medical research. Today, he is far away from all that, as his voice reverberates through this little San Francisco room, lifting it up and away from the desperate streets of the Tenderloin neighborhood below. The notes vibrate in his wavy blond hair and green eyes, and in the tumor that’s growing quickly on his right hearing nerve  -  the only hearing nerve he has left. Onno is hearing the sound fill his body while he still can, before neurofibromatosis takes the other nerve away.

There comes a moment in any quest when it pivots from idea to reality. The blueprint is sketched, the parts are assembled, and someone hits the ignition — and with that, the idea is no longer in a safe, controlled space. Other people are watching now, influencing it, invested in it. The transition is equal parts exciting and scary. There is no turning back now.

Read Part Four in full:

Onno Faber. Photo courtesy of Winnie Wintermeyer, NEO.LIFE

In October 2019, Onno Faber made the familiar drive from San Francisco to a specialized clinic in Los Angeles to lie down on a gantry and slip his head inside the giant white tube of an MRI machine. He’d been making the trip every three months for about five years, to glimpse the tumor growing on his right auditory nerve.

For a year and a half, as Onno slugged down 40 pills a week and suffered through side effects from fever to brain fog, the tumor held steady. And within that pause Onno kept hearing through his right ear (another tumor took out his left hearing nerve years ago). He kept singing to himself in his apartment in San Francisco, retained his ability to walk steadily, balance, and ski with friends. He bought time - time to put his entrepreneurialism and his cadre of tech-savvy friends to work pursuing treatments for his rare genetic disorder and the thousands of others that receive little investment from pharma companies that prefer big markets. 

The next day, the results came back: the tumor had grown 40 percent. 

Read Part Five in the series:

NEO.LIFE asks the big questions about how we’re engineering our own evolution.
Learn more

Filter News

Filter by Date
Category
Reset

Luke’s Story

Read More

Charlotte’s Story

Read More

Eden P Study

Currently pregnant? Please consider taking part in the Eden P study

Read More

Jen’s NF1 story

Jen praises the great support received since her NF1 diagnosis, allowing her to thrive & achieve a 1st class degree.

Read More

Eden P for healthcare professionals

Healthcare professionals, who provide support to expectant parents with NF1 are invited to take part in the Eden P study

Read More

Nicole’s story

Nicole has NF2, she describes the preparations and the absolute joyful experience of the birth of her son Lewis

Read More

Johnathan’s story

Johnathon's family are spreading awareness of the importance of attending health checks and advocating for vulnerable people

Read More

CAR Research - exploring family planning decisions

Research Advisors required to help explore what influences decisions about having children and what support would be helpful

Read More

Corporate Fundraising 2024

Find out some of the different ways your company can support Nerve Tumours UK

Read More

Masterclasses in NF: Constitutional Mismatch Repair Deficiency Syndrome as Differential Diagnosis to NF1/Legius Syndrome - Prof. Dr. Katharina Wimmer

Constitutional Mismatch Repair Deficiency Syndrome as Differential Diagnosis to NF1/Legius Syndrome

Prof. Dr. Katharina Wimmer, Medical University of Innsbruck

Masterclasses in NF: Rare NF1-Associated Tumors in Adults - Eric Legius & Prof. Ellen Denayer

Masterclasses in NF: Rare NF1-Associated Tumors in Adults

Eric Legius, MD, PhD, University Hospital Leuven

Prof. Ellen Denayer, University Hospital Leuven

Masterclasses in NF: Optimising Hearing Outcomes in NF2-Related Schwannomatosis - Simon Freeman

Masterclasses in NF: Optimising Hearing Outcomes in NF2-Related Schwannomatosis

Simon Freeman, MPhil FRCS, Manchester Royal Infirmary and Salford Royal Hospital

Masterclasses in NF: NF1 Dermatological Manifestations - Pierre Wolkenstein, Laura Fertitta & Sirkku Peltonen

Masterclasses in NF: NF1 Dermatological Manifestations

Pierre Wolkenstein, MD, PhD, Hopital Henri-Mondor, Paris, France

Laura Fertitta, MD, Hôpital Universitaire Henri Mondor

Sirkku Peltonen, MD, PhD, University of Gothenberg, Sweden

Masterclasses in NF: Breast Cancer in NF1 - Gareth Evans

Masterclasses in NF: Breast Cancer in NF1

Gareth Evans, MD, University of Manchester, UK

Masterclasses in NF: Pain in Non-NF2-Related Schwannomatosis - David Pang

Masterclasses in NF: Pain in Non-NF2-Related Schwannomatosis

David Pang, MD, ChB. Guys and St Thomas' Hospital NHS Trust, London

Masterclasses in NF: Distinguishing Non-NF2-Related from NF2-Related Schwannomatosis - Clinical and Genetic Approaches - Said Farschtschi

Masterclasses in NF: Distinguishing Non-NF2-Related from NF2-Related Schwannomatosis - Clinical and Genetic Approaches

Said Farschtschi, MD, University Medical Center, Hamburg-Eppendorf, Germany

Masterclasses in NF: NF1 Pre-Implantation Genetic Diagnosis - Eric Legius & Prof. Ellen Denayer

Masterclasses in NF: NF1 Pre-Implantation Genetic Diagnosis

Eric Legius, MD, PHD, University Hospital of Leuven, Belgium

Prof. Ellen Denayer, University Hospital of Leuven, Belgium

NF2 Working Together: from a tentative diagnosis and beyond

Understanding the impact that a tentative diagnosis has on a parent. Information and access to the existing NTUK and Specialist Nerve Tumours medical and non medical care network.

NF1 Working Together Part 2: from a tentative diagnosis and beyond

Understanding the impact that a tentative diagnosis has on a parent. Information and access to the existing NTUK and Specialist Nerve Tumours medical and non medical care network.

NF1 Working Together Part 1: from a tentative diagnosis and beyond

Understanding  the impact that a tentative diagnosis has on a parent. Information and access to the existing NTUK and Specialist Nerve Tumours medical and non medical care network.

Masterclasses in NF: Surgery in NF2 - Michel Kalamarides & Andrew King

Masterclasses in NF: Surgery in NF2

Michel Kalamarides, MD, PhD, Hôpital Pitié-Salpêtrière, Paris, France

Prof Andrew King, MBBS FRCS FRCS(SN), Salford Royal Hospital, Manchester, United Kingdom. Member of the MAB of Nerve Tumours UK

Masterclasses in NF: Cognition and Behaviour in NF1: Phenotype and Treatment Approaches - Shruti Garg, Andre Rietman

Masterclasses in NF: Cognition and Behaviour in NF1: Phenotype and Treatment Approaches

Dr Shruti Garg, MBBS, MRCPsych, MMedSci, PhD, Royal Manchester Children’s Hospital, United Kingdom. Member of the MAB of Nerve Tumours UK

Andre Rietman, PhD, Erasmus University Medical Center, Rotterdam, Netherlands

Masterclasses in NF: Emotional Challenges in NF1, NF2 and Schwannomatosis - Susie Henley, Thomas Pletschko & Verena Rosenmayr

Masterclasses in NF: Emotional Challenges in NF1, NF2 and Schwannomatosis

Susie Henley, DClinPsy, PhD, Guy’s and St Thomas’ NHS Foundation Trust, London UK

Thomas Pletschko, PhD, Medical University of Vienna, Austria

Verena Rosenmayr, Clinical Psychologist, Medical University of Vienna, Austria

Masterclasses in NF: NF1 Pediatric Management - Rianne Oostenbrink

Masterclasses in NF: NF1 Pediatric Management

Rianne Oostenbrink, MD, PhD, Erasmus University Medical Center, Rotterdam, Netherlands

Masterclasses in NF: Associated Glioma in Children - the Optic Pathway and Beyond - Amedeo Azizi

Masterclasses in NF: Associated Glioma in Children - the Optic Pathway and Beyond

Amedeo Azizi, MD, PhD, Head of the Paediatric Neurofibromatosis Program and Paediatric Neuro-Oncology Program, Medical University of Vienna, Austria

Masterclasses in NF: NF1 Orthopedic Manifestations - Eric Legius and Christophe Glorion

Masterclasses in NF: NF1 Orthopedic Manifestations

Eric Legius, MD, PhD. Head of Clinical Genetics Department of the University Hospital Leuven, Belgium

Christophe Glorion, MD, PhD, Department of Paediatric Orthopedic and Traumatologic Surgery, Hopital Necker-Enfants Malades, Paris, France. 

Masterclasses in NF: NF1 Malignant Peripheral Nerve Sheath Tumours - Rosalie Ferner and Viktor-Felix Mautner

Masterclasses in NF: NF1 Malignant Peripheral Nerve Sheath Tumours

Prof Rosalie Ferner, Consultant Neurologist and Lead Clinician for Neurofibromatosis, Guy's and St. Thomas' NHS Foundation Trust, London. Member of the MAB of Nerve Tumours UK and Trustee of Nerve Tumours UK

Viktor-Felix Mautner, MD, PhD. University Medical Centre in Hamburg-Eppendorf, Germany. Head of NF Outpatient Department

Masterclasses in NF - Neurofibromatosis Type 1: Cutaneous Neurofibromas - Pierre Wolkenstein and Sirkku Peltonen

Masterclasses in NF - Neurofibromatosis Type 1: Cutaneous Neurofibromas

Pierre Wolkenstein, MD, PhD. Hopital Henri-Mondor, Paris, France. Head of the Department of Dermatology

Sirkku Peltonen MD, PhD. University of Gothenberg, Sweden. Professor of Dermatology

INFER (International NF Educational Resources) is a series of online educational lectures for medical professionals by leading neurofibromatosis experts. The Masterclasses take place online approximately once a month, each on a different topic, and include real-time interaction between the expert presenter and the participants. The presentations are conducted in English, with real-time audio interpretation available in 6 additional languages: French, German, Italian, Portuguese, Russian, and Spanish. A recording of each INFER masterclass is then be made available online in each language for those who could not attend an event. INFER is an initiative of Children’s Tumor Foundation Europe, supported by an educational grant from AstraZeneca. https://ctfeurope.org/research/masterclasses-in-nf

BPNA Keynote Lecture - Prof Rosalie Ferner - Neurofibromatosis 1 in the 21st Century

‘Neurofibromatosis 1 in the 21st Century’

Keynote Lecture at the 48th British Paediatric Neurology Association Annual Scientific Meeting on 21st January 2022

Prof Rosalie Ferner, Consultant Neurologist and Lead Clinician for Neurofibromatosis, Guy's and St. Thomas' NHS Foundation Trust, London. Member of the MAB of Nerve Tumours UK and Trustee of Nerve Tumours UK